A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
NCT ID: NCT02049099
Last Updated: 2016-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1658 participants
OBSERVATIONAL
2014-03-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Project to Update the Study of Congenital Haemophilia in Spain
NCT01959555
A Feasibility Study to Collect Data in Patients With Haemophilia
NCT00798499
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
NCT03741881
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830
Study Evaluating Approach to Treatment of Haemophilia A and B in Spain
NCT00581438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with Factor VIII/Factor IX products initiated at least 24 months before inclusion in the study.
* Informed consent is obtained from the patient or patient's legal representative (as applicable according to legal regulation).
Exclusion Criteria
2 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swedish Orphan Biovitrum
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Lethagen, MD
Role: STUDY_DIRECTOR
Swedish Orphan Biovitrum AB (publ)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swedish Orphan Biovitrum Investigational Site
Brussels, , Belgium
Swedish Orphan Biovitrum Investigational Site
Montpellier, , France
Swedish Orphan Biovitrum Investigational Site
Nantes, , France
Swedish Orphan Biovitrum Investigational Site
Bonn, , Germany
Swedish Orphan Biovitrum Investigational Site
Leipzig, , Germany
Swedish Orphan Biovitrum Investigational Site
Florence, , Italy
Swedish Orphan Biovitrum Investigational Site
Milan, , Italy
Swedish Orphan Biovitrum Investigational Site
Vicenza, , Italy
Swedish Orphan Biovitrum Investigational Site
Barcelona, , Spain
Swedish Orphan Biovitrum Investigational Site
Madrid, , Spain
Swedish Orphan Biovitrum Investigational Site
Stockholm, , Sweden
UKHCDO
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sobi.HAEM89-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.